Home   /  Find a Trial  /  See All TrialsHELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page Print
 

See All Trials

QuickViews

Match by Tumor Type:

Newly Diagnosed (Stage I-III)
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)
Inflammatory Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)

View by Trial Type:

Treatment:

 

Non-Treatment:

see All Trials

Sort by zip code:  

 

Share

Facebook
Twitter
Twitter

 
1 trials contain the search term(s): "NCT02536339"

Perjeta and Herceptin for HER2-Positive Brain Metastases

An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA) (NCT02536339)

Summary

Pertuzumab (Perjeta®) and trastuzumab (Herceptin®) are targeted therapies used to treat HER2-positive breast cancer. This study is investigating the safety and effectiveness of giving Perjeta along with a high dose of Herceptin to treat HER2-positive metastatic breast cancer that has spread to the brain. To be eligible, participants must have had their brain metastases recur or progress after radiation therapy.
This is a Phase II trial